--- title: "Vijay Suhag, M.D. | Sutter Health" url: "https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Investigators](https://www.sutterhealth.org/research/investigators) / 4. Vijay Suhag, M.D. ![Vijay Suhag, M.D.](https://dyn.mktgcdn.com/p/2btOt-t3CAH93pukF8v-Lma0a0_MC_Om9YclxsoFI5Y/fit=crop,gravity=auto,dpr=2,width=240,height=240) # Vijay Suhag, M.D. Investigator [View profile](https://www.sutterhealth.org/find-provider/dr-vijay-suhag-1046244499) [View All Publications from PubMed](https://pubmed.ncbi.nlm.nih.gov/19851170/) Vijay S. Suhag, MD, is a hematologist-oncologist at the Sutter Roseville Cancer Center. He is board certified in internal medicine and is a National Cancer Institute-designated cancer researcher. Dr. Suhag investigates novel therapies for hematological malignancies and solid tumor cancers. He participates in cooperative group cancer clinical trials testing new immunotherapies and targeted therapies. Dr. Suhag obtained an MD from University College of Medical Sciences in New Delhi, India. He completed residency training in internal medicine at Drexel University College of Medicine in Philadelphia, PA, and a fellowship in hematology and medical oncology at Washington Hospital Center in Washington, DC. 8 Medical Plaza Drive Suite 300 Roseville, CA 95661 ## Clinical trials - Clinical trial ### [Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-early-stage-non-small-cell-lung-cancer-beamion-lung-3-2084403277) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Open to Enrollment - Clinical trial ### [Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer](https://www.sutterhealth.org/research/clinical-trials/adjuvant-monotherapy-vs-standard-of-care-early-stage-resectable-non-small-cell-lung-cancer-2082765455) Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations **Status:** Coming Soon - Clinical trial ### [Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005](https://www.sutterhealth.org/research/clinical-trials/adjuvant-non-small-cell-lung-cancer-c5851005-padl1nk-005-2064313501) PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) **Status:** Open to Enrollment - Clinical trial ### [Advanced or Metastatic Non-Small Cell Lung Cancer C6461001](https://www.sutterhealth.org/research/clinical-trials/advanced-or-metastatic-non-small-cell-lung-cancer-c6461001-2046372288) An Interventional Phase 3, Double-blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination with Chemotherapy Versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Locally Advanced or Metastatic Non-small Cell Lung Cancer **Status:** Open to Enrollment ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Investigators","item":"https://www.sutterhealth.org/research/investigators"},{"@type":"ListItem","position":4,"name":"Vijay Suhag, M.D."}]} ``` ```json {"@context":"https://schema.org","@type":"ProfilePage","@id":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006#profilepage","url":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006","name":"Vijay Suhag, M.D.","dateModified":"2026-06-09","breadcrumb":{"@id":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006#breadcrumblist"},"primaryImageOfPage":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/2btOt-t3CAH93pukF8v-Lma0a0_MC_Om9YclxsoFI5Y/460x460.webp","width":460,"height":460},"mainEntity":{"@id":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006"}} ``` ```json {"@context":"https://schema.org","@type":"Person","@id":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006","name":"Vijay Suhag, M.D.","givenName":"Vijay","familyName":"Suhag","honorificSuffix":"M.D.","description":"Vijay S. Suhag, MD, is a hematologist-oncologist at the Sutter Roseville Cancer Center. He is board certified in internal medicine and is a National Cancer Institute-designated cancer researcher. Dr. Suhag investigates novel therapies for hematological malignancies and solid tumor cancers. He participates in cooperative group cancer clinical trials testing new immunotherapies and targeted therapies. Dr. Suhag obtained an MD from University College of Medical Sciences in New Delhi, India. He completed residency training in internal medicine at Drexel University College of Medicine in Philadelphia, PA, and a fellowship in hematology and medical oncology at Washington Hospital Center in Washington, DC.","image":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/2btOt-t3CAH93pukF8v-Lma0a0_MC_Om9YclxsoFI5Y/460x460.webp","representativeOfPage":true},"address":{"@type":"PostalAddress","streetAddress":"8 Medical Plaza Drive Suite 300","addressLocality":"Roseville","addressRegion":"CA","postalCode":"95661","addressCountry":"US"},"affiliation":{"@id":"https://www.sutterhealth.org/#medicalorganization"},"mainEntityOfPage":{"@id":"https://www.sutterhealth.org/research/investigators/vijay-suhag-md-1049681006#profilepage"},"sameAs":"https://www.sutterhealth.org/find-provider/dr-vijay-suhag-1046244499"} ```